TY - JOUR
T1 - 90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine
T2 - A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies
AU - Picozzi, Vincent J.
AU - Ramanathan, Ramesh K.
AU - Lowery, Maeve A.
AU - Ocean, Allyson J.
AU - Mitchel, Edith P.
AU - O'neil, Bert H.
AU - Guarino, Michael J.
AU - Conkling, Paul R.
AU - Cohen, Steven J.
AU - Bahary, Nathan
AU - Frank, Richard C.
AU - Dragovich, Tomislav
AU - Bridges, Benjamin B.
AU - Braiteh, Fadi S.
AU - Starodub, Alexander N.
AU - Lee, Fa Chyi
AU - Gribbin, Thomas E.
AU - Richards, Donald A.
AU - Lee, Marie
AU - Korn, Ronald L.
AU - Pandit-Taskar, Neeta
AU - Goldsmith, Stanley J.
AU - Intenzo, Charles M.
AU - Sheikh, Arif
AU - Manzone, Timothy C.
AU - Horne, Heather
AU - Sharkey, Robert M.
AU - Wegener, William A.
AU - O'reilly, Eileen M.
AU - Goldenberg, David M.
AU - Von Hoff, Daniel D.
N1 - Publisher Copyright:
© 2015 The Authors.
PY - 2015/6/7
Y1 - 2015/6/7
N2 - Background For patients with metastatic pancreatic adenocarcinoma, there are no approved or established treatments beyond the 2nd line. A Phase Ib study of fractionated radioimmunotherapy was undertaken in this setting, administering 90Y-clivatuzumab tetraxetan (yttrium-90-radiolabelled humanised antibody targeting pancreatic adenocarcinoma mucin) with or without low radiosensitising doses of gemcitabine. Methods Fifty-eight patients with three (2-7) median prior treatments were treated on Arm A (N = 29, 90Y-clivatuzumab tetraxetan, weekly 6.5 mCi/m2 doses × 3, plus gemcitabine, weekly 200 mg/m2 doses × 4 starting 1 week earlier) or Arm B (N = 29, 90Y-clivatuzumab tetraxetan alone, weekly 6.5 mCi/m2 doses × 3), repeating cycles after 4-week delays. Safety was the primary endpoint; efficacy was also evaluated. Results Cytopaenias (predominantly transient thrombocytopenia) were the only significant toxicities. Fifty-three patients (27 Arm A, 26 Arm B, 91% overall) completed ≥1 full treatment cycles, with 23 (12 Arm A, 11 Arm B; 40%) receiving multiple cycles, including seven (6 Arm A, 1 Arm B; 12%) given 3-9 cycles. Two patients in Arm A had partial responses by RECIST criteria. Kaplan-Meier overall survival (OS) appeared improved in Arm A versus B (hazard ratio [HR] 0.55, 95% CI: 0.29-0.86; P = 0.017, log-rank) and the median OS for Arm A versus Arm B increased to 7.9 versus 3.4 months with multiple cycles (HR 0.32, P = 0.004), including three patients in Arm A surviving >1 year. Conclusions Clinical studies of 90Y-clivatuzumab tetraxetan combined with low-dose gemcitabine appear feasible in metastatic pancreatic cancer patients beyond 2nd line and a Phase III trial of this combination is now underway in this setting.
AB - Background For patients with metastatic pancreatic adenocarcinoma, there are no approved or established treatments beyond the 2nd line. A Phase Ib study of fractionated radioimmunotherapy was undertaken in this setting, administering 90Y-clivatuzumab tetraxetan (yttrium-90-radiolabelled humanised antibody targeting pancreatic adenocarcinoma mucin) with or without low radiosensitising doses of gemcitabine. Methods Fifty-eight patients with three (2-7) median prior treatments were treated on Arm A (N = 29, 90Y-clivatuzumab tetraxetan, weekly 6.5 mCi/m2 doses × 3, plus gemcitabine, weekly 200 mg/m2 doses × 4 starting 1 week earlier) or Arm B (N = 29, 90Y-clivatuzumab tetraxetan alone, weekly 6.5 mCi/m2 doses × 3), repeating cycles after 4-week delays. Safety was the primary endpoint; efficacy was also evaluated. Results Cytopaenias (predominantly transient thrombocytopenia) were the only significant toxicities. Fifty-three patients (27 Arm A, 26 Arm B, 91% overall) completed ≥1 full treatment cycles, with 23 (12 Arm A, 11 Arm B; 40%) receiving multiple cycles, including seven (6 Arm A, 1 Arm B; 12%) given 3-9 cycles. Two patients in Arm A had partial responses by RECIST criteria. Kaplan-Meier overall survival (OS) appeared improved in Arm A versus B (hazard ratio [HR] 0.55, 95% CI: 0.29-0.86; P = 0.017, log-rank) and the median OS for Arm A versus Arm B increased to 7.9 versus 3.4 months with multiple cycles (HR 0.32, P = 0.004), including three patients in Arm A surviving >1 year. Conclusions Clinical studies of 90Y-clivatuzumab tetraxetan combined with low-dose gemcitabine appear feasible in metastatic pancreatic cancer patients beyond 2nd line and a Phase III trial of this combination is now underway in this setting.
KW - Antibody
KW - Clivatuzumab tetraxetan
KW - Gemcitabine
KW - Pancreatic cancer
KW - Radioimmunotherapy
KW - Yttrium-90
UR - http://www.scopus.com/inward/record.url?scp=84939550103&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939550103&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2015.06.119
DO - 10.1016/j.ejca.2015.06.119
M3 - Article
C2 - 26187510
AN - SCOPUS:84939550103
SN - 0959-8049
VL - 51
SP - 1857
EP - 1864
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 14
M1 - 9522
ER -